Suppr超能文献

糖鞘脂介导的小窝蛋白-1寡聚化

Glycosphingolipid Mediated Caveolin-1 Oligomerization.

作者信息

Shu Liming, Shayman James A

机构信息

Nephrology Division, Department of Internal Medicine, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109, USA.

出版信息

J Glycomics Lipidomics. 2012 Feb 18;Suppl 2:1-6. doi: 10.4172/2153-0637.S2-003.

Abstract

We have previously demonstrated an association between the accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and the loss of high molecular weight oligomers in the aortas of α-galactosidase A-knockout mice, a model of Fabry disease. In the present study the molecular basis for the association between glycosphingolipids and caveolin-1 oligomerization was further investigated. Cellular glycosphingolipids were selectively depleted by treatment with a series of sphingolipid synthesis inhibitors, including D--ethylenedioxyphenyl-2-palmitoylamino-3-pyrrolidino-propanol, fumonisin B1 and myriocin. The depletion of glycosphingolipids resulted in the loss of high molecular mass oligomers of caveolin-1 in plasma membranes of cultured ECV-304 cells as well as in the caveolar fractions of Hela cells as measured by immunoblotting. The disruption of caveolin-1 high molecular weight oligomer formation caused by changes of composition of glycosphingolipids may be directly involved in the interruption of cellular functions including caveolar stabilization, membrane trafficking and signal transduction. These results suggest a specific role for glycosphingolipidsin the caveolar co-localization and oligomerization of caveolin-1.

摘要

我们之前已经证明,在法布里病模型α-半乳糖苷酶A基因敲除小鼠的主动脉中,糖鞘脂球三糖神经酰胺(Gb3)的积累与高分子量寡聚物的丢失之间存在关联。在本研究中,我们进一步探究了糖鞘脂与小窝蛋白-1寡聚化之间关联的分子基础。通过用一系列鞘脂合成抑制剂处理,包括D-二乙二氧基苯基-2-棕榈酰氨基-3-吡咯烷基-丙醇、伏马菌素B1和米里霉素,选择性地消耗细胞糖鞘脂。通过免疫印迹法检测,糖鞘脂的消耗导致培养的ECV-304细胞膜以及Hela细胞小窝组分中小窝蛋白-1高分子量寡聚物的丢失。由糖鞘脂组成变化引起的小窝蛋白-1高分子量寡聚物形成的破坏,可能直接参与包括小窝稳定、膜运输和信号转导在内的细胞功能的中断。这些结果表明糖鞘脂在小窝蛋白-1的小窝共定位和寡聚化中具有特定作用。

相似文献

1
Glycosphingolipid Mediated Caveolin-1 Oligomerization.
J Glycomics Lipidomics. 2012 Feb 18;Suppl 2:1-6. doi: 10.4172/2153-0637.S2-003.
2
Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
J Biol Chem. 2007 Jul 20;282(29):20960-7. doi: 10.1074/jbc.M702436200. Epub 2007 May 29.
3
Agents for the treatment of glycosphingolipid storage disorders.
Curr Drug Metab. 2001 Sep;2(3):331-8. doi: 10.2174/1389200013338414.
4
5
6
Regulation of phospholipase C-gamma activity by glycosphingolipids.
J Biol Chem. 2002 May 24;277(21):18447-53. doi: 10.1074/jbc.M111363200. Epub 2002 Mar 8.
7
Improved inhibitors of glucosylceramide synthase.
J Biol Chem. 1999 May 21;274(21):14662-9. doi: 10.1074/jbc.274.21.14662.
8
An in vitro model of Fabry disease.
J Am Soc Nephrol. 2005 Sep;16(9):2636-45. doi: 10.1681/ASN.2005040383. Epub 2005 Jul 20.
9
Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.
Future Sci OA. 2016 Oct 13;2(4):FSO147. doi: 10.4155/fsoa-2016-0027. eCollection 2016 Dec.
10
Caveolae respond to cell stretch and contribute to stretch-induced signaling.
J Cell Sci. 2011 Nov 1;124(Pt 21):3581-90. doi: 10.1242/jcs.084376.

引用本文的文献

1
Strategies for Delivering Nanoparticles across Tumor Blood Vessels.
Adv Funct Mater. 2021 Feb 17;31(8). doi: 10.1002/adfm.202007363. Epub 2020 Nov 12.
2
Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches.
Front Physiol. 2022 Mar 31;13:828093. doi: 10.3389/fphys.2022.828093. eCollection 2022.
3
Differences in the expression of caveolin-1 isoforms in cancer-associated and normal fibroblasts of patients with oral squamous cell carcinoma.
Clin Oral Investig. 2021 Oct;25(10):5823-5831. doi: 10.1007/s00784-021-03887-8. Epub 2021 Mar 27.
4
Glycosphingolipids and neuroinflammation in Parkinson's disease.
Mol Neurodegener. 2020 Oct 17;15(1):59. doi: 10.1186/s13024-020-00408-1.
5
Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease.
Semin Nephrol. 2018 Mar;38(2):183-192. doi: 10.1016/j.semnephrol.2018.01.007.
7
Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.
Kidney Int. 2014 Jul;86(1):58-66. doi: 10.1038/ki.2013.520. Epub 2014 Jan 8.

本文引用的文献

1
A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells.
J Biol Chem. 2011 Nov 25;286(47):40900-10. doi: 10.1074/jbc.M111.286146. Epub 2011 Sep 23.
3
Decreased nitric oxide bioavailability in a mouse model of Fabry disease.
J Am Soc Nephrol. 2009 Sep;20(9):1975-85. doi: 10.1681/ASN.2008111190. Epub 2009 Jul 23.
4
Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1156-63. doi: 10.1111/j.1440-1681.2008.04984.x. Epub 2008 Jun 18.
5
Regulation of tumor phenotypes by caveolin-1 and sphingolipid-controlled membrane signaling complexes.
Biochim Biophys Acta. 2008 Mar;1780(3):585-96. doi: 10.1016/j.bbagen.2007.08.002. Epub 2007 Aug 19.
6
Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
J Biol Chem. 2007 Jul 20;282(29):20960-7. doi: 10.1074/jbc.M702436200. Epub 2007 May 29.
7
Biogenesis of caveolae: a structural model for caveolin-induced domain formation.
J Cell Sci. 2006 Mar 1;119(Pt 5):787-96. doi: 10.1242/jcs.02853.
9
An in vitro model of Fabry disease.
J Am Soc Nephrol. 2005 Sep;16(9):2636-45. doi: 10.1681/ASN.2005040383. Epub 2005 Jul 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验